Shuttle Pharmaceuticals expands patent coverage on HDAC inhibitor platform

Shuttle Pharmaceuticals announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase inhibitor platform technology titled “Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated Activation and Methods of Use Thereof.”